NCT04993586View on ClinicalTrials.gov

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

422

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

December 10, 2021

Study Completion Date

September 23, 2022

Conditions
COVID-19 Lower Respiratory Infection
Interventions
BIOLOGICAL

AG0302-COVID19 for Intramuscular Injection

Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals

BIOLOGICAL

AG0302-COVID19 for Intramuscular Injection

Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

AG0302-COVID19 for Intramuscular Injection

Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

AG0302-COVID19 for Intradermal Injection

Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals

BIOLOGICAL

AG0302-COVID19 for Intradermal Injection

Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals

Trial Locations (6)

286-8520

IUHW Narita Hospital, Narita

565-0853

Medical Corporation Heishinkai OCROM Clinic, Suita

160-0008

Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku

160-0017

Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku

171-0014

Sekino Clinical Pharmacology Clinic, Toshima-ku

532-0003

Medical Corporation Heishinkai OPHAC Hospital, Osaka

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

AnGes, Inc.

INDUSTRY